Daré Bioscience Announces Memorandum of Understanding with CONRAD

Biotech Investing

Daré Bioscience is set to enter into an agreement with a postcoital test clinical trial of Ovaprene wherein CONRAD will provide certain clinical and regulatory services.

Daré Bioscience (NASDAQ:DARE) is set to enter into an agreement with a postcoital test clinical trial of Ovaprene wherein CONRAD will provide certain clinical and regulatory services.
As quoted in the press release:

CONRAD is a non-profit organization established to improve reproductive health globally under a cooperative agreement between Eastern Virginia Medical School and the U. S. Agency for International Development (USAID). CONRAD oversaw the successful development and approval of the Caya® diaphragm, the U.S. Food and Drug Administration’s (FDA’s) most recently approved barrier contraceptive device in combination with a locally-acting spermiostatic agent. Since its founding in 1986, CONRAD has been internationally renowned for its leadership in developing new contraceptive products.
“CONRAD has played a leadership role in the development of multiple intravaginal rings for the vaginal delivery of contraceptive agents and drugs and of barrier method contraceptives. We feel this expertise combined with their experience in running PCT assessments on other barrier method contraceptives that are currently FDA approved, make them an ideal partner for the conduct of Ovaprene®’s PCT clinical trial,” stated Sabrina Martucci Johnson, President and CEO of Daré. “Daré has established relationships, and intends to work closely, with non-profit developers such as CONRAD, with clinical and regulatory expertise in reproductive health and with a proven track record of FDA success. We believe working with CONRAD will provide for the efficient use of capital and time to advance Ovaprene®.”

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×